ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research-Reference-Cited by-同舟云学术

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research

Published:2021-03 Issue:3 Volume:32 Page:337-350
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Belli C.,Penault-Llorca F.,Ladanyi M.,Normanno N.,Scoazec J.-Y.,Lacroix L.,Reis-Filho J.S.,Subbiah V.,Gainor J.F.,Endris V.,Repetto M.,Drilon A.,Scarpa A.,André F.,Douillard J.-Y.,Curigliano G.

Funder

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference102 articles.

1. Advances in kinase targeting: current clinical use and clinical trials;Rask-Andersen;Trends Pharmacol Sci,2014

2. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors;Marcus;Clin Cancer Res,2019

3. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade;Le;Science,2017

4. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children;Drilon;N Engl J Med,2018

5. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study;Laetsch;Lancet Oncol,2018

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study;Lung Cancer;2024-10

2. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

3. Predictive biomarkers in thyroid cancer in the current molecular-morphology paradigm;Surgical and Experimental Pathology;2024-08-14

4. High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods;Virchows Archiv;2024-08-09

5. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001;Journal of Clinical Oncology;2024-08-02